Top Markets
Coin of the day
Eagle Pharmaceuticals, Inc. Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

EGRX
Rang în acțiuni #33346
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on... Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Preț acțiune
$0.595
Ultima sincronizare: 2026-08-13
Capitalizare de piață
$7.83M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
-81.41%
Țară
US
Tranzacționează Eagle Pharmaceuticals, Inc. (EGRX)

Categorie

Câștiguri pentru Eagle Pharmaceuticals, Inc. (EGRX)
Câștiguri în 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Eagle Pharmaceuticals, Inc., câștigurile actuale ale companiei sunt 0. În anul 2026, compania a înregistrat un câștig de 0, egal cu câștigului din 2026, care a fost de 0. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Eagle Pharmaceuticals, Inc. din 2026 până în 2026
Câștiguri la sfârșitul fiecărui an
An Câștiguri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Câștiguri pentru companii similare sau concurente